AroCell AB

Equities

AROC

SE0003883990

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 10:43:23 2024-04-26 am EDT			5-day change	1st Jan Change
0.372 ^SEK	+0.54%		-3.88%	-14.87%

Apr. 18	Swedish Diagnostics Company AroCell Secures US Patent	MT
Feb. 22	AroCell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

AroCell : Presentation at LabRoots 2024

March 04, 2024 at 03:52 am EST

Mar 4, 2024

Martin Shaw, Business Development at AroCell, held a presentation on the Thymidine Kinase 1 immunoassay, highlighting its significance as a valuable translational biomarker from drug discovery through to clinical trials. You can see the presentation below.

Attachments

Original Link
Permalink

Disclaimer

AroCell AB published this content on 04 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 March 2024 08:52:01 UTC.

Latest news about AroCell AB

Swedish Diagnostics Company AroCell Secures US Patent	Apr. 18	MT
AroCell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
AroCell AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
AroCell Names CFO Goes on Parental Leave, Interim CFO Named	Feb. 01	MT
AroCell AB Announces Chief Financial Officer Changes	Feb. 01	CI
AroCell Wins Regulatory Nod for Typhoid Fever Rapid Test in Ethiopia	Jan. 25	MT
AroCell AB Obtains Regulatory Approval for TUBEX® TF in Ethiopia	Jan. 25	CI
AroCell AB Announces Results of Serum Tk1 Protein Levels Can Predict the Survival of Patients with Metastatic Prostate Cancer Patients	Jan. 15	CI
AroCell AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
AroCell AB Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer	23-09-18	CI
AroCell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
AroCell AB Signs Additional Agreement with ZECEN Biotech Co., Ltd	23-07-17	CI
AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03	CI
AroCell AB Announces TK1 together with PSA can predict more than 10 years differences in survival in men with prostate cancer	23-03-09	CI
Arocell AB Announces Improved Early Detection of Ovarian Cancer with Dual Biomarker Algorithm	23-03-06	CI
AroCell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-23	CI
AroCell Signs Distribution Agreement in Ethiopia	23-02-01	CI
AroCell AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-27	CI
AroCell Signs Distribution Agreement with MM African Technology Covering Zambia and Malawi	22-10-19	CI
AroCell To Register TPS CLIA Tumor Marker In Chinese Market	22-09-06	MT
AroCell AB Expands Its Presence in the Chinese Market	22-09-06	CI
AroCell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-17	CI
AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument	22-06-13	CI
AroCell AB Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market	22-05-12	CI
Attana Plans to Move Production of Consumables to AroCell AB	22-05-05	CI

Chart AroCell AB

Duration

Period

More charts

Company Profile

AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for AroCell AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AROCELL AB	-14.87%	7.82M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research